N-末端原脑钠肽对充血性心力衰竭患者预后评估的价值

目的 探讨血浆N-末端原脑钠肽(Nt-proBNP)评估充血性心力衰竭预后的价值.方法 选择充血性心力衰竭患者107例,治疗稳定后出院,随访患者的再次入院次数和死亡率;采用双抗体夹心酶联免疫吸附(ELISA)法测定血浆Nt-proBNP浓度.结果 NYHA分级中Ⅱ级、Ⅲ级、Ⅳ级患者血浆Nt-pmBNP浓度分别为(1 129.8±383.2)ng/L、(5 849.7±567.6)ng/L、(9 506.3±492.4)ng/L(P＜0.01),NYHA分级与血浆Nt-proBNP水平呈明显的正相关系(r=0.7593,P＜0.01);平均再住院次数分别为(0.85±0.96)、(1.98±0.86)、(2.58±0.91)(P＜0.01);死亡率分别为8.3%、12.5%、45.2%(P＜0.01).结论 血浆Nt-pmBNP水平对充血性心力衰竭患者预后的评估具有较高临床价值.

Evaluating prognostic value of plasma Nt-proBNP in patients with congestive heart failure

Objective To determine the evaluating prognostic value of plasma Nt-proBNP in patients with congestive heart failure.Methods 107 patients with congestive heart failure were included in this study,followed the degree of rehospitalization and mortality rate of the cured patients after left hospital.The plasma concentrations of Nt-proBNP were measured by enzymelinked immunozorbent assay(ELISA).Results Concentrations of Nt-proB-NP of Ⅱ,Ⅲ,Ⅳ classincation were(1129.8±383.2),(5849.7±567.6),(9506.3±492.4)ng/L in NYHA functional classification respectively(P＜0.01);the plasma level of Nt-proBNP had significant positive correlation with NYHA functional classification(r=0.759,P＜0.01).The degree of rehospitalization were(0.85±0.96),(1.98±0.86),(2.58±0.91)respectively(P＜0.01);mortality rate were 8.3%,12.5%,45.2%respectively(P＜0.01).Conclusion Plasma Nt-proBNP level may be the more important clinic value in evaluating prognosis in patients with congestive heart failure.